DE60230655D1 - Arzneimittel mit einer kombination aus einem antithrombotischen mittel und einem pyrazolon-derivat - Google Patents

Arzneimittel mit einer kombination aus einem antithrombotischen mittel und einem pyrazolon-derivat

Info

Publication number
DE60230655D1
DE60230655D1 DE60230655T DE60230655T DE60230655D1 DE 60230655 D1 DE60230655 D1 DE 60230655D1 DE 60230655 T DE60230655 T DE 60230655T DE 60230655 T DE60230655 T DE 60230655T DE 60230655 D1 DE60230655 D1 DE 60230655D1
Authority
DE
Germany
Prior art keywords
score
alkyl
patients
thrombus
hydroxyalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230655T
Other languages
English (en)
Inventor
Keiichi Yamada
Katsumi Kurita
Tadashi Tanaka
Masahiko Tanaka
Jyunichi Eguchi
Satoshi Yuki
Narihiko Yoshii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of DE60230655D1 publication Critical patent/DE60230655D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60230655T 2001-09-14 2002-09-13 Arzneimittel mit einer kombination aus einem antithrombotischen mittel und einem pyrazolon-derivat Expired - Lifetime DE60230655D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001279645 2001-09-14
JP2001365032 2001-11-29
PCT/JP2002/009425 WO2003024445A1 (fr) 2001-09-14 2002-09-13 Medicaments comprenant un antithrombotique en association avec un derive pyrazolone

Publications (1)

Publication Number Publication Date
DE60230655D1 true DE60230655D1 (de) 2009-02-12

Family

ID=26622230

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230655T Expired - Lifetime DE60230655D1 (de) 2001-09-14 2002-09-13 Arzneimittel mit einer kombination aus einem antithrombotischen mittel und einem pyrazolon-derivat

Country Status (10)

Country Link
US (1) US8183206B2 (de)
EP (1) EP1437137B1 (de)
JP (2) JP4521186B2 (de)
KR (1) KR20040044514A (de)
CN (1) CN100398104C (de)
AT (1) ATE418983T1 (de)
CA (1) CA2460141C (de)
DE (1) DE60230655D1 (de)
ES (1) ES2318036T3 (de)
WO (1) WO2003024445A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004331653A (ja) * 2003-04-14 2004-11-25 Mitsubishi Pharma Corp 疼痛の予防及び／又は治療剤
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
CN101524352A (zh) 2008-03-04 2009-09-09 江苏先声药物研究有限公司 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物
AU2009316624B2 (en) * 2008-11-20 2013-03-14 Techno Guard Co., Ltd. Pyrazolone Derivative Formulations
CN106420688B (zh) 2016-10-08 2017-11-10 西北大学 Idhp制备预防和治疗冠状动脉粥样硬化疾病药物的应用
ES2928785T3 (es) * 2017-10-13 2022-11-22 Treeway Tw001 B V Sal de edaravona

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK169672B1 (da) 1985-05-20 1995-01-09 Mitsubishi Chem Ind Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater
JPH03130028A (ja) 1989-08-08 1991-06-03 Nippon Alum Mfg Co Ltd 給餌装置
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia

Also Published As

Publication number Publication date
WO2003024445A1 (fr) 2003-03-27
ES2318036T3 (es) 2009-05-01
JP2010043132A (ja) 2010-02-25
CN100398104C (zh) 2008-07-02
KR20040044514A (ko) 2004-05-28
JPWO2003024445A1 (ja) 2004-12-24
ATE418983T1 (de) 2009-01-15
EP1437137A4 (de) 2006-05-10
US8183206B2 (en) 2012-05-22
CA2460141A1 (en) 2003-03-27
JP4521186B2 (ja) 2010-08-11
EP1437137B1 (de) 2008-12-31
JP5081890B2 (ja) 2012-11-28
CA2460141C (en) 2012-01-10
EP1437137A1 (de) 2004-07-14
CN1555261A (zh) 2004-12-15
US20050009896A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
IL263245A (en) Method for the treatment of liver failure
ES2557453T3 (es) Derivados de isoquinolina, quinolina y quinazolina como inhibidores de la señalización de Hedgehog
JP2017128617A (ja) １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
CO5611172A2 (es) Stents recubiertos con n-{5-[4-(4-metil-piperazino-metil) -benozilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina
DE69613365T2 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
ID28267A (id) Turunan benzamida dan penggunaannya sebagai inhibitor sitokina
MXPA04001400A (es) Derivados de tiazolilo 2,4,5-tri-substituidos y su actividad anti-inflamatoria.
TNSN05165A1 (fr) Derives de pyrrolopyrimidine
TR200100300T2 (tr) Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
KR960705807A (ko) 항혈전성 아미디노페닐알라닌 및 아미디노피리딜알라닌 유도체(Antithrombotic Amidinophenylalanine and Amidinopyridylalanine Derivatives)
KR20020018201A (ko) 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물
WO2016044441A1 (en) Sgc stimulators
DE60230655D1 (de) Arzneimittel mit einer kombination aus einem antithrombotischen mittel und einem pyrazolon-derivat
ZA200105066B (en) Alkynyl containing hydroxamic acid compounds as TACE inhibitors.
DE60137442D1 (de) 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung
US20080317857A1 (en) V-Atpase Inhibitors of Use in the Treatment of Septic Shock
TW200633714A (en) Drugs for the treatment and/or prophylaxis of gastroparesis symptom
JP2023075371A (ja) 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
US20110319398A1 (en) Inhibition of yops translocation
EP0228094A3 (en) Pyrimidoû5,4-b¨û1,4¨oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimidoû5,4-b¨û1,4¨oxazine derivatives
KR20030046469A (ko) 염증성 장질환 치료제
TH51768A (th) สารประกอบคาร์บาฟีเนม การใช้ของสารดังกล่าว และสารประกอบตัวกลางสำหรับสารดังกล่าว
JPWO2002048096A1 (ja) ヒドラゾン誘導体およびその医薬用途
TH54052A (th) โพลีไซคลิคเอริลและเฮทเทอโรเอริลไพริโดนที่ถูกแทนที่ที่เป็นประโยชน์สำหรับการยับยั้งแบบเลือกของแคสเคตการจับตัวเป็นก้อน

Legal Events

Date Code Title Description
8364 No opposition during term of opposition